AlzeCure Pharma: New preclinical data strengthens ACD856 - Redeye

Redeye comments on AlzeCure Pharma presenting new preclinical data for NeuroRestore ACD856 at the AD/PD Conference in Copenhagen (17–21 March 2026). The presentation provides deeper mechanistic validation and reinforces the asset’s potential in multiple CNS indications.

Länk till analysen i sin helhet: https://www.redeye.se/research/1157453/alzecure-pharma-preclinical-data-strengthens-acd856?utm_source=finwire&utm_medium=RSS